NYSE:EW Edwards Lifesciences - EW Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. $82.12 -2.39 (-2.83%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$81.39▼$84.1450-Day Range$72.27▼$84.5152-Week Range$67.13▼$131.10Volume4.74 million shsAverage Volume3.34 million shsMarket Capitalization$50.77 billionP/E Ratio33.66Dividend YieldN/APrice Target$89.74 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Edwards Lifesciences MarketRank™ ForecastAnalyst RatingHold2.47 Rating ScoreUpside/Downside9.3% Upside$89.74 Price TargetShort InterestHealthy2.28% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.28Based on 45 Articles This WeekInsider TradingSelling Shares$6.93 M Sold Last QuarterProj. Earnings Growth12.70%From $2.52 to $2.84 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector103rd out of 1,025 stocksSurgical Appliances & Supplies Industry6th out of 23 stocks 2.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 10 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $89.74, Edwards Lifesciences has a forecasted upside of 9.3% from its current price of $82.12.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.28% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 9.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 2.4 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 45 news articles for Edwards Lifesciences this week, compared to 6 articles on an average week.Search Interest23 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 156% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,933,324.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions80.35% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.70% in the coming year, from $2.52 to $2.84 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 33.66, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 33.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 138.88.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.79. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 8.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edwards Lifesciences (NYSE:EW) StockEdwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.Read More Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Stock News HeadlinesFebruary 4, 2023 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Forecasted to Post Q1 2023 Earnings of $0.65 Per ShareFebruary 3, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM)February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.February 3, 2023 | americanbankingnews.comCanaccord Genuity Group Increases Edwards Lifesciences (NYSE:EW) Price Target to $76.00February 3, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Downgraded to Underperform at Sanford C. BernsteinFebruary 3, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Sees Strong Trading Volume After Better-Than-Expected EarningsFebruary 2, 2023 | finance.yahoo.comEdwards Lifesciences Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 2, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Announces Quarterly Earnings ResultsFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.February 2, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Price Target Raised to $86.00 at Truist FinancialFebruary 1, 2023 | finanznachrichten.deEdwards Lifesciences Corporation: Edwards Lifesciences Reports Fourth Quarter ResultsFebruary 1, 2023 | finance.yahoo.comEdwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call TranscriptFebruary 1, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Q4 Earnings Top, Margins IncreaseFebruary 1, 2023 | finance.yahoo.comEdwards Lifesciences Surges As Signs Point To 'Green Shoots Around The Corner'February 1, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesFebruary 1, 2023 | benzinga.comEdwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023February 1, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Cut to "Neutral" at Piper SandlerFebruary 1, 2023 | americanbankingnews.comEdwards Lifesciences (NYSE:EW) Stock Rating Lowered by StockNews.comFebruary 1, 2023 | seekingalpha.comEdwards Lifesciences Corp (EW) Q4 2022 Earnings Call TranscriptJanuary 31, 2023 | markets.businessinsider.comEdwards Lifesciences Corp. Q4 Profit Increases, beats estimatesJanuary 31, 2023 | marketwatch.comEdwards Lifesciences Corp. stock rises Tuesday, still underperforms marketJanuary 31, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Q4 Earnings and Revenues Surpass EstimatesJanuary 31, 2023 | finance.yahoo.comEdwards Expects 2023 Sales To Outperform The 'Challenging Environment'January 31, 2023 | za.investing.comEdwards Lifesciences cut to underperform at Bernstein as organic growth slowsJanuary 31, 2023 | msn.comHere's How Much $1000 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth TodayJanuary 31, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Edwards Lifesciences (EW), Envista Holdings (NVST)January 30, 2023 | msn.comA Preview Of Edwards Lifesciences's EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Company Calendar Last Earnings1/31/2023Today2/05/2023Next Earnings (Estimated)4/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees15,700Year Founded1958Price Target and Rating Average Stock Price Forecast$89.74 High Stock Price Forecast$134.00 Low Stock Price Forecast$66.00 Forecasted Upside/Downside+9.3%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$2.44 Trailing P/E Ratio33.66 Forward P/E Ratio32.59 P/E Growth4.79Net Income$1.50 billion Net Margins28.27% Pretax Margin32.84% Return on Equity26.05% Return on Assets18.36% Debt Debt-to-Equity Ratio0.10 Current Ratio3.03 Quick Ratio3.00 Sales & Book Value Annual Sales$5.38 billion Price / Sales9.43 Cash Flow$2.46 per share Price / Cash Flow33.32 Book Value$9.39 per share Price / Book8.75Miscellaneous Outstanding Shares618,260,000Free Float610,284,000Market Cap$50.77 billion OptionableOptionable Beta1.00 Social Links Key ExecutivesMichael A. MussallemChairman & Chief Executive OfficerBernard J. ZovighianPresidentScott B. UllemChief Financial Officer & Vice PresidentTodd J. BrintonChief Scientific Officer & VP-Advanced TechnologyLinda J. ParkSecretary, Senior VP & Associate General CounselKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGZimmer BiometNYSE:ZBHAlign TechnologyNASDAQ:ALGNTakeda PharmaceuticalNYSE:TAKView All CompetitorsInsiders & InstitutionsSecurian Asset Management Inc.Sold 835 shares on 2/3/2023Ownership: 0.008%Spire Wealth ManagementSold 203 shares on 2/3/2023Ownership: 0.001%Ellevest Inc.Sold 993 shares on 2/3/2023Ownership: 0.001%Oakworth Capital Inc.Sold 491 shares on 2/3/2023Ownership: 0.001%U.S. Capital Wealth Advisors LLCBought 1,001 shares on 2/3/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EW Stock - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price forecast for 2023? 19 brokers have issued 12 month price objectives for Edwards Lifesciences' stock. Their EW share price forecasts range from $66.00 to $134.00. On average, they anticipate the company's share price to reach $89.74 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2023? Edwards Lifesciences' stock was trading at $74.61 on January 1st, 2023. Since then, EW stock has increased by 10.1% and is now trading at $82.12. View the best growth stocks for 2023 here. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a drop in short interest in January. As of January 15th, there was short interest totaling 13,930,000 shares, a drop of 9.2% from the December 31st total of 15,340,000 shares. Based on an average daily trading volume, of 5,170,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 2.3% of the company's stock are short sold. View Edwards Lifesciences' Short Interest. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) released its earnings results on Tuesday, January, 31st. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.61 by $0.03. The medical research company earned $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Edwards Lifesciences had a net margin of 28.27% and a trailing twelve-month return on equity of 26.05%. The company's revenue for the quarter was up 1.5% on a year-over-year basis. During the same period last year, the company posted $0.51 EPS. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its FY23 earnings guidance on Tuesday, January, 31st. The company provided EPS guidance of $2.45-$2.60 for the period, compared to the consensus estimate of $2.50. The company issued revenue guidance of $5.60-$6.0 billion, compared to the consensus revenue estimate of $5.78 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (1.24%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), DekaBank Deutsche Girozentrale (0.24%), New York State Common Retirement Fund (0.20%), Bank of Montreal Can (0.20%) and CCLA Investment Management (0.17%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $82.12. How much money does Edwards Lifesciences make? Edwards Lifesciences (NYSE:EW) has a market capitalization of $50.77 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.50 billion in net income (profit) each year or $2.44 on an earnings per share basis. How many employees does Edwards Lifesciences have? The company employs 15,700 workers across the globe. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More How can I contact Edwards Lifesciences? Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525. This page (NYSE:EW) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.